Antitrust Chronicle® – Patents, Drugs & Antitrust
Spring 2014, Volume 4, Number 2
Dear Readers, This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to sell samples of restricted distribution […]
In this issue
Oct 1, 2021
Dec 22, 2015
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
In case you missed it...

April
This Chronicle explores the rapidly evolving intersection of foreign direct investment and technology, a space where traditional assumptions about openness, control, and market integration are being fundamentally reworked.

March
This Chronicle brings together contributions that explore the evolving relationship between industrial policy, competition, regulation & technological change from complementary angles.

February
This month’s TechREG Chronicle focuses on online consumer protection, at a moment when regulators on both sides of the Atlantic are reassessing how legacy consumer-protection frameworks apply in digital, data-driven markets.
See more Chronicles by year:
Featured News
Cooley Expands Global Antitrust Practice With Senior Leadership Appointment
May 4, 2026 by
CPI
Meatpacking Giants Face Federal Antitrust Scrutiny Over Consumer Prices
May 4, 2026 by
CPI
Maryland Becomes First State to Ban Algorithmic Pricing in Grocery Stores
May 4, 2026 by
CPI
Unanimous Senate Judiciary Committee Advances GUARD Act
May 4, 2026 by
CPI
EU Commission Pushes for Huawei, ZTE Exclusion Under New Cybersecurity Rules
May 4, 2026 by
CPI